Making the case for the development of a vaccination against hepatitis E virus.
Hepatitis E virus (HEV) infection is a global problem that affects 20 million individuals, and cause acute hepatitis in 3.5 million, with approximately 70,000 deaths worldwide per year. While the acute disease is generally self-limited, however, it may progress to fatal fulminant liver failure in certain individuals. Contaminated water supplies disseminate this virus through the faecal-oral route, and swine is thought to be its zoonotic reservoir. Attempts have been made to develop effective HEV vaccines, and two candidates have undergone successful clinical trials. In this review, we discuss HEV epidemiology, genotypes, microbiological structure, as well as the most recent advances in vaccination developments.
Department of Gastroenterology, Al-Mouassat University Hospital, Damascus, Syria.
Samir
S
Haffar
Fateh
F
Bazerbachi
John R
JR
Lake
D002986:Clinical Trials as Topic; D016679:Genome, Viral / Q000235:genetics*; D005838:Genotype; D016751:Hepatitis E / Q000453:epidemiology* / Q000517:prevention & control*; D016752:Hepatitis E virus / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D014761:Viral Hepatitis Vaccines / Q000494:pharmacology*
D014761:Viral Hepatitis Vaccines
HEV vaccine; hepatitis E virus (HEV); primary prevention; vaccination; viral hepatitis